ESMO pays tribute to Professor José Baselga.
作者信息
Peters S, Tabernero J, Cervantes A, Banerjee S, Giuliani R, Lordick F
机构信息
CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Vall d'Hebron University Hospital, Barcelona, Spain.
出版信息
Immunooncol Technol. 2021 Apr 27;9:100027. doi: 10.1016/j.iotech.2021.100027. eCollection 2021 Mar.
Abstract
摘要
相似文献
1
ESMO pays tribute to Professor José Baselga.欧洲肿瘤内科学会向何塞·巴塞尔加教授致敬。
Immunooncol Technol. 2021 Apr 27;9:100027. doi: 10.1016/j.iotech.2021.100027. eCollection 2021 Mar.
2
ESMO pays tribute to Professor José Baselga.
Ann Oncol. 2021 Jul;32(7):823-824. doi: 10.1016/j.annonc.2021.04.001. Epub 2021 Apr 27.
3
Corrigendum to 'Remembering Professor José Baselga': [ESMO Open Volume 6, Issue 3, June 2021, 100121].《缅怀何塞·巴塞尔加教授》勘误：[《ESMO 开放》第 6 卷，第 3 期，2021 年 6 月，100121]
ESMO Open. 2021 Aug;6(4):100221. doi: 10.1016/j.esmoop.2021.100221. Epub 2021 Jul 7.
4
Professor Patricia Rocco pays tribute to Professor Paolo Pelosi.帕特里夏·罗科教授向保罗·佩洛西教授致敬。
Ann Intensive Care. 2023 Jun 24;13(1):55. doi: 10.1186/s13613-023-01151-8.
5
Foreword to symposium "forty years of epithelial transport-specificity and commonality": a tribute to Professor José A Zadunaisky.“上皮运输的特异性与共性四十年”研讨会前言：向何塞·A·扎杜奈斯基教授致敬
J Exp Zool A Comp Exp Biol. 2003 Nov 1;300(1):3-4. doi: 10.1002/jez.a.10302.
6
José Manuel Baselga (1959-2021).
Science. 2021 Apr 23;372(6540):350. doi: 10.1126/science.abi7805.
7
José Baselga (1959-2021).
Cancer Cell. 2021 May 10;39(5):581-582. doi: 10.1016/j.ccell.2021.04.003. Epub 2021 Apr 29.
8
José Baselga 1959-2021.
Nat Cancer. 2021 May;2(5):479-480. doi: 10.1038/s43018-021-00209-5.
9
José Baselga M.D., Ph.D. (1959-2021) leading cancer researcher and oncologist.何塞·巴塞尔加医学博士、哲学博士（1959 - 2021），杰出的癌症研究员和肿瘤学家。
J Exp Clin Cancer Res. 2021 May 7;40(1):156. doi: 10.1186/s13046-021-01966-y.
10
Professor José Miguel Barea (1942-2018): a tribute to an inspiring scientist.何塞·米格尔·巴雷亚教授（1942-2018）：一位鼓舞人心的科学家的致敬。
Mycorrhiza. 2018 Aug;28(5-6):573-575. doi: 10.1007/s00572-018-0837-9.
本文引用的文献
1
Implementing Genome-Driven Oncology.实施基因组驱动的肿瘤学。
Cell. 2017 Feb 9;168(4):584-599. doi: 10.1016/j.cell.2016.12.015.
2
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.CLEOPATRA 中的生物标志物分析：一项安慰剂对照的 III 期研究，评估曲妥珠单抗联合帕妥珠单抗在人表皮生长因子受体 2 阳性、一线转移性乳腺癌中的疗效。
J Clin Oncol. 2014 Nov 20;32(33):3753-61. doi: 10.1200/JCO.2013.54.5384. Epub 2014 Oct 20.
3
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.依维莫司联合依西美坦治疗激素受体阳性、人表皮生长因子受体2阴性的晚期乳腺癌：BOLERO-2研究的总生存结果†
Ann Oncol. 2014 Dec;25(12):2357-2362. doi: 10.1093/annonc/mdu456. Epub 2014 Sep 17.
4
Bringing precision medicine to the clinic: from genomic profiling to the power of clinical observation.将精准医学引入临床：从基因组分析到临床观察的力量。
Ann Oncol. 2013 Aug;24(8):1956-7. doi: 10.1093/annonc/mdt273.
5
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.依维莫司用于绝经后激素受体阳性的晚期乳腺癌。
N Engl J Med. 2012 Feb 9;366(6):520-9. doi: 10.1056/NEJMoa1109653. Epub 2011 Dec 7.
6
CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.CLEOPATRA：帕妥珠单抗联合曲妥珠单抗治疗人表皮生长因子受体 2 阳性转移性乳腺癌的 III 期评估。
Clin Breast Cancer. 2010 Dec 1;10(6):489-91. doi: 10.3816/CBC.2010.n.065.
7
Creating a stronger front against cancer: ESMO and ECCO join forces.
Ann Oncol. 2008 Aug;19(8):1367-1368. doi: 10.1093/annonc/mdn425.
8
Why the epidermal growth factor receptor? The rationale for cancer therapy.为什么是表皮生长因子受体？癌症治疗的基本原理。
Oncologist. 2002;7 Suppl 4:2-8. doi: 10.1634/theoncologist.7-suppl_4-2.
9
The epidermal growth factor receptor as a target for therapy in breast carcinoma.表皮生长因子受体作为乳腺癌治疗的靶点。
Breast Cancer Res Treat. 1994 Jan;29(1):127-38. doi: 10.1007/BF00666188.
10
Growth regulation of human renal carcinoma cells: role of transforming growth factor alpha.人肾癌细胞的生长调节：转化生长因子α的作用
Cancer Res. 1992 Jun 15;52(12):3335-9.
Zotero 插件